PMGroup/Visions4Health unveil Excellence in Healthcare Partnerships Awards

June 26, 2025
Medical Communications CHASE, Corporate, Excellence in Healthcare Partnerships Awards, NHS ConfedExpo, PMGroup, Visions4Health

PMGroup Worldwide and Visions4Health have launched the Excellence in Healthcare Partnerships (EHP) Awards to recognise collaborations that deliver measurable benefits …

Photo of patient

FDA grants orphan drug designation to antibody-mediated rejection treatment

June 26, 2025
Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation

Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …

money_pills_2

Oxeltis secures €800,000 grant to advance antiviral candidate for emerging tropical viruses

June 26, 2025
Medical Communications, Research and Development Corporate, Defense Innovation Agency, National Research Agency, Oxeltis, RNA viruses, Virology, contract research organisation

Oxeltis, a French contract research organisation specialising in medicinal and organic chemistry, has announced that it will lead the BUNYANTIVIR …

blood_test

Roche candidate shows early promise for treating haemophilia A

June 25, 2025
Research and Development Chugai, Haematology, Roche, clinical trial, haemophilia a, prophylactic therapy

Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. …

weight-2036971_960_720

Novo Nordisk’s therapy delivers significant weight loss in trial

June 25, 2025
Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions

Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …

Opterion Health strengthens board with appointments of Rice Powell and Mark Hahn

June 25, 2025
Research and Development CEO, Nephrology, Opterion Health, board of directors, cfo, chronic kidney disease, dialysis solution

Swiss life sciences company Opterion Health has appointed two senior industry figures to its board of directors: Rice Powell, former …

PLL Therapeutics appoints renowned ALS expert Philippe Corcia to scientific board

June 25, 2025
Research and Development ALS Reference Centre, National ALS Motor Neuron Study Group, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis (ALS), scientific board

PLL Therapeutics has appointed leading amyotrophic lateral sclerosis (ALS) researcher Philippe Corcia to its scientific board, marking a strategic move …

NHS ConfedExpo 2025: a platform for change in UK health and care

June 24, 2025
Medical Communications Accenture, AstraZeneca, Corporate, Excellence in healthcare Partnership (EHP) Awards, Manchester, NHS ConfedExpo, NHS Confederation, NHS England, Novartis UK, Visions4Health

This year’s NHS ConfedExpo took place on 11 to 12 June at Manchester Central, bringing together around 9,000 attendees. Among …

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma

June 24, 2025
Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …

Neurizon confirms positive results for prospective ALS treatment

June 23, 2025
Research and Development Neurizon Therapeutics, Neurology, amyotrophic lateral sclerosis, blood-brain barrier, clinical data, neurodegenerative diseases

Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain …

blood-1813410_960_720

Novo Nordisk presents promising findings for haemophilia treatment

June 23, 2025
Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval

Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …

louis-reed-pwckf7l4-no-unsplash_5

Terumo BCT showcases new CAR-T workflow enabling faster cell expansion

June 20, 2025
Manufacturing and Production CAR-T cell manufacturing, Devices, EULV, Eureka Biotechnology, Terumo Blood and Cell Technologies, cell therapy, eureka, gene therapy

Terumo Blood and Cell Technologies (Terumo BCT) has unveiled a new automated workflow that consolidates three critical CAR-T manufacturing steps …

NICE recommends spevigo for rare and severe psoriasis flares

June 20, 2025
Medical Communications, Research and Development Dermatology, NHS, National Institute for Health and Care Excellence, generalised pustular psoriasis

The National Institute for Health and Care Excellence (NICE) has recommended Spevigo (spesolimab) for the treatment of generalised pustular psoriasis …

First UK patient treated with CSL Behring’s gene therapy for Haemophilia B

June 20, 2025
Research and Development CSL Behring, Haematology, NHS England, cell therapy, gene therapy, haemophilia B, prophylactic infusions

CSL Behring has announced that the first patient in the UK has received HEMGENIX (etranacogene dezaparvovec) through the NHS, marking …

Eyestem completes phase 1 trial of retinal cell therapy with promising vision gains

June 20, 2025
Research and Development Eyestem Research, Opthalmology, cell therapy, clinical trial, dry age-related macular degeneration, geographic atrophy

Eyestem Research has announced the successful completion of its phase 1 trial evaluating Eyecyte-RPE, an investigational cell therapy for geographic …

Celltrion opens new UK headquarters in Uxbridge to drive long-term growth

June 19, 2025
Research and Development Corporate, Pharmacy, biosimilar medicines, celltrion

Celltrion, focused on the development of biosimilar medicines, has officially opened its new UK headquarters in the Charter Building, Uxbridge, …

The Gateway to Local Adoption Series

Latest content